Rapamycin, Autophagy, and Alzheimer's Disease.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive impairment and multiple pathological lesions. At the molecular level, AD is characterized by overt amyloid β (Aβ) production and tau hyper-phosphorylation. Hence, pharmacological agents that can attenuate Aβ accumulation and tau hyper-phosphorylation have potential promise for treatment of AD. Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), is believed to be one of such pharmacological agents. It is neuroprotective in neurodegenerative diseases and its primary action is thought to be via enhancement of autophagy, a biological process that not only facilitates the clearance of mutant proteins but also significantly reduces the build-up of toxic protein aggregates such as Aβ. Since rapamycin enhancement of autophagy has been associated with abrogation of AD pathological processes such as clearance of Aβ and neurofibrillary tangles (NTFs) as well as reduction of tau hyper-phosphorylation and improvement of cognition, rapamycin is emerging as a potential therapeutic compound for AD.

[1]  J. Larrick,et al.  Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases. , 2011, Rejuvenation research.

[2]  Jiankun Liu,et al.  mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease. , 2013, Molecular medicine reports.

[3]  Marta Martínez-Vicente,et al.  Fighting neurodegeneration with rapamycin: mechanistic insights , 2011, Nature Reviews Neuroscience.

[4]  M. Antoch,et al.  Rapamycin extends maximal lifespan in cancer-prone mice. , 2010, The American journal of pathology.

[5]  E. Klann,et al.  Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[6]  Yun Zhang,et al.  Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels , 2009, British journal of pharmacology.

[7]  C. Long-Smith,et al.  Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. , 2012, Biochemical Society transactions.

[8]  J. Mao,et al.  Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. , 2013, Biochemical and biophysical research communications.

[9]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[10]  O. Ghribi,et al.  Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus , 2011, Molecular Neurodegeneration.

[11]  Robert H Logie,et al.  Dual-task performance in Alzheimer's disease, mild cognitive impairment, and normal ageing. , 2011, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[12]  A. Salminen,et al.  Regulation of the aging process by autophagy. , 2009, Trends in molecular medicine.

[13]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[14]  H. Eldar-Finkelman,et al.  Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model , 2012, The Journal of Biological Chemistry.

[15]  Smita Majumder,et al.  Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits , 2011, Alzheimer's & Dementia.

[16]  Isabella Pisano,et al.  Rapamycin reduces oxidative stress in frataxin-deficient yeast cells. , 2012, Mitochondrion.

[17]  R. Morris,et al.  Brief treatment with rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response. , 1992, Immunology letters.

[18]  Yan Chen Shang,et al.  Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders , 2010, Oxidative medicine and cellular longevity.

[19]  P. Davies,et al.  Novel synthetic small‐molecule activators of AMPK as enhancers of autophagy and amyloid‐β peptide degradation , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Yuhua Fan,et al.  Autophagosomes accumulation is associated with β‐amyloid deposits and secondary damage in the thalamus after focal cortical infarction in hypertensive rats , 2012, Journal of neurochemistry.

[21]  M. Djavaheri-Mergny,et al.  The complex interplay between autophagy and NF-κB signaling pathways in cancer cells. , 2011, American journal of cancer research.

[22]  T. Ohm,et al.  Coupling of Mammalian Target of Rapamycin with Phosphoinositide 3-Kinase Signaling Pathway Regulates Protein Phosphatase 2A- and Glycogen Synthase Kinase-3β-dependent Phosphorylation of Tau* , 2008, Journal of Biological Chemistry.

[23]  Alcino J. Silva,et al.  mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies , 2013, Aging cell.

[24]  B. Giunta,et al.  Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. , 2010, Biochemical and biophysical research communications.

[25]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[26]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[27]  A. Wada,et al.  Homologous posttranscriptional regulation of insulin-like growth factor-I receptor level via glycogen synthase kinase-3β and mammalian target of rapamycin in adrenal chromaffin cells: Effect on tau phosphorylation , 2010, Neuropharmacology.

[28]  S. Austad,et al.  Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice , 2012, Neuroscience.

[29]  R. Kayed,et al.  Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain , 2005, Brain Research.

[30]  Liang-Jun Yan,et al.  Telomere Shortening and Alzheimer’s Disease , 2012, NeuroMolecular Medicine.

[31]  Matt Kaeberlein,et al.  Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.

[32]  S. Schreiber,et al.  Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington’s Disease Models and Enhance Killing of Mycobacteria by Macrophages , 2007, Autophagy.

[33]  Jie Chen,et al.  regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. , 2004, Diabetes.

[34]  A. Cuervo,et al.  Autophagy and disease: always two sides to a problem , 2012, The Journal of pathology.

[35]  Tsuyoshi Morita,et al.  Specification of Neuronal Polarity Regulated by Local Translation of CRMP2 and Tau via the mTOR-p70S6K Pathway* , 2009, The Journal of Biological Chemistry.

[36]  M. Hart,et al.  Over‐expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's‐like deficits in mice modeling the disease , 2013, Journal of neurochemistry.

[37]  D. Walsh,et al.  Alzheimer's disease: synaptic dysfunction and Aβ , 2009, Molecular Neurodegeneration.

[38]  R. Kayed,et al.  Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. , 2005, Brain research.

[39]  M. Wataya-Kaneda,et al.  A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. , 2012, Archives of dermatology.

[40]  E. White,et al.  Role of Autophagy in Cancer Prevention , 2011, Cancer Prevention Research.

[41]  P. Codogno,et al.  Autophagy, signaling and obesity. , 2012, Pharmacological research.

[42]  Shaohui Wang,et al.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. , 2012, Future neurology.

[43]  Shaohui Wang,et al.  Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade , 2012, International journal of molecular sciences.

[44]  L. Partridge,et al.  A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice , 2012, Cell cycle.

[45]  Lloyd A Greene,et al.  Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.

[46]  W. Chiu,et al.  Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection. , 2013, The Journal of surgical research.

[47]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[48]  C. Proud,et al.  mTOR's role in ageing: protein synthesis or autophagy? , 2009, Aging.

[49]  C. Sutherland,et al.  Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling , 2010, Proceedings of the National Academy of Sciences.

[50]  M. Ratinaud,et al.  Autophagic subpopulation sorting by sedimentation field-flow fractionation. , 2012, Analytical chemistry.

[51]  F. Collins,et al.  Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome , 2012, Autophagy.

[52]  X. Qiao,et al.  Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase , 2013, Neurochemistry International.

[53]  Theo van Laar,et al.  APP and APLP1 are degraded through autophagy in response to proteasome inhibition in neuronal cells , 2011, Protein & Cell.

[54]  A. Sorisky,et al.  Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1 , 2004, International Journal of Obesity.

[55]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[56]  S. Gandy,et al.  Apomorphine and Alzheimer Aβ: Roles for regulated α cleavage, autophagy, and antioxidation? , 2011, Annals of neurology.

[57]  J. Adamski,et al.  Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. , 2013, The Journal of nutritional biochemistry.

[58]  Daniela Galimberti,et al.  Inflammation and oxidative damage in Alzheimer's disease: friend or foe? , 2011, Frontiers in Bioscience.

[59]  J T O'Brien,et al.  Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment , 1997, Psychological Medicine.

[60]  A. Gingras,et al.  A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Taga,et al.  Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH‐SY5Y cells , 2011, FEBS letters.

[62]  Jue-an Jiang,et al.  Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. , 2013, International journal of molecular medicine.

[63]  W. Hader,et al.  Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. , 2012, Folia neuropathologica.

[64]  D. Price,et al.  Neurofibrillary tangles and β-amyloid deposits in Alzheimer's disease , 1991, Current Opinion in Neurobiology.

[65]  V. Anisimov,et al.  Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.

[66]  P. Greengard,et al.  A small‐molecule enhancer of autophagy decreases levels of Aβ and APP‐CTF via Atg5‐dependent autophagy pathway , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  A Role of the Mammalian Target of Rapamycin (mTOR) in Glutamate-Induced Down-regulation of Tuberous Sclerosis Complex Proteins 2 (TSC2) , 2012, Journal of Molecular Neuroscience.

[68]  J. Lindeboom,et al.  Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. , 2004, European journal of pharmacology.

[69]  B. Winblad,et al.  Levels of mTOR and its downstream targets 4E‐BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain , 2005, The FEBS journal.

[70]  G. Perry,et al.  beta PP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. , 1996, The American journal of pathology.

[71]  Bin Zhao,et al.  Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease? , 2012, Journal of neuroscience research.

[72]  D. Rubinsztein,et al.  Rapamycin pre-treatment protects against apoptosis. , 2006, Human molecular genetics.

[73]  K. Park,et al.  Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions , 2012, Autophagy.

[74]  B. Lamb,et al.  Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. , 2004, The international journal of biochemistry & cell biology.

[75]  Jin-A Lee,et al.  Regulation of Abeta pathology by beclin 1: a protective role for autophagy? , 2008, The Journal of clinical investigation.

[76]  Liping Huang,et al.  Upexpression of Beclin-1-Dependent Autophagy Protects Against Beta-amyloid-Induced Cell Injury in PC12 Cells , 2013, Journal of Molecular Neuroscience.

[77]  Roger Gil,et al.  The immunosuppressant rapamycin exacerbates neurotoxicity of Aβ peptide , 2006, Journal of neuroscience research.

[78]  Cora O' Neill.  PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. , 2013 .

[79]  M. Antoch,et al.  Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice , 2012, Aging.

[80]  S. Wesselborg,et al.  Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks , 2011, Molecular and Cellular Biology.

[81]  K. Herrup,et al.  The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events , 2009, Molecular Neurodegeneration.

[82]  D. Price,et al.  Neurofibrillary tangles and beta-amyloid deposits in Alzheimer's disease. , 1991, Current opinion in neurobiology.

[83]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[84]  D. Rubinsztein,et al.  A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. , 2008, Human molecular genetics.

[85]  N. Sigal,et al.  Suppression of B cell activation by cyclosporin A, FK506 and rapamycin , 1990, European journal of immunology.

[86]  D. Rubinsztein,et al.  Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? , 2006, Molecular aspects of medicine.

[87]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[88]  A. Caccamo,et al.  Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling , 2012, Aging cell.

[89]  E. Masliah,et al.  Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex , 2010, PloS one.

[90]  Jianling Xie,et al.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes , 2011, Cellular and Molecular Life Sciences.

[91]  W. Fu,et al.  Autophagy protects neuron from Aβ-induced cytotoxicity , 2009, Autophagy.

[92]  K. Maiese,et al.  Mammalian target of rapamycin signaling in diabetic cardiovascular disease , 2012, Cardiovascular Diabetology.

[93]  M. Antoch,et al.  New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis , 2012, Aging.

[94]  P. Codogno,et al.  Lysosome positioning coordinates mTORC1 activity and autophagy , 2011, Nature Cell Biology.

[95]  Shaohui Wang,et al.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin , 2012, Progress in Neurobiology.

[96]  Ralph A. Nixon,et al.  Autophagy, amyloidogenesis and Alzheimer disease , 2007, Journal of Cell Science.

[97]  P. Agostinho,et al.  Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. , 2010, Current pharmaceutical design.

[98]  S. Correia,et al.  Effects of rapamycin and TOR on aging and memory: implications for Alzheimer’s disease , 2011, Journal of neurochemistry.

[99]  M. Murakami,et al.  Insulin-induced neurite-like process outgrowth: Acceleration of tau protein synthesis via a phosphoinositide 3-kinase∼mammalian target of rapamycin pathway , 2011, Neurochemistry International.

[100]  Shulin Li.  The Possible Cellular Mechanism for Extending Lifespan of Mice with Rapamycin , 2009, Biological Procedures Online.

[101]  B. Juntermanns,et al.  Tumor growth effects of rapamycin on human biliary tract cancer cells , 2012, European Journal of Medical Research.

[102]  A. Khanna.  MECHANISM OF THE COMBINATION IMMUNOSUPPRESSIVE EFFECTS OF RAPAMYCIN WITH EITHER CYCLOSPORINE OR TACROLIMUS , 2000, Transplantation.

[103]  Jaetaek Kim,et al.  Nutritional Status and Cardiac Autophagy , 2013, Diabetes & metabolism journal.

[104]  L. Breydo,et al.  Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice , 2012, Molecular Neurodegeneration.

[105]  S. Paik,et al.  Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein , 2004, Journal of neuroscience research.

[106]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.